Clinical Trial Update: A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety of pegcetacoplan (APL-2) as an add-on to standard of care in paroxysmal nocturnal hemoglobinuria (PNH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Status: COMPLETED | Results posted: 2021-01-08